Should chemotherapy be used in nonmetastatic prostate cancer?—No.
Docetaxel was the first drug shown to improve survival for patients with metastatic castration-resistant prostate cancer, and recent data demonstrate that earlier use of docetaxel in the metastatic castration-naïve setting has an even greater impact on overall survival.1 These results and recent reports describing the antitumor activity of docetaxel in clinical trials that included patients with nonmetastatic disease have renewed interest in docetaxel therapy in earlier stages of prostate cancer.
Graff JN, Alumkal JJ, Beer TM. Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?. JAMA Oncol. 2017;3(1):11-12. doi:10.1001/jamaoncol.2016.3623